Martinez-Maldonado M, Allen J C, Inagaki C, Tsaparas N, Schwartz A
J Clin Invest. 1972 Oct;51(10):2544-51. doi: 10.1172/JCI107070.
The role of renal Na(+),K(+)-ATPase in sodium reabsorption was further examined in dogs in which digoxin, a specific inhibitor of the enzyme system, was infused into one renal artery in doses ranging from 0.4 to 0.9 mug/kg/min (low dose) and from 1.0 to 4.0 mug/kg/min (high dose). A significant natriuresis occurred with both dose ranges which was accompanied by inhibition of Na(+),K(+)-ATPase of cortex and medulla in the infused kidney. Despite over 90% enzyme inhibition in many experiments, at least 80% of the filtered sodium continued to be reabsorbed. The per cent change in enzyme activity correlated with the rate of digoxin administration and the total dose administered but not with changes in sodium excretion. Changes in medullary Na(+),K(+)-ATPase activity, however, bore a direct relationship to alterations in fractional solute free water reabsorption (T(c) (H2O)). Inhibition of cortical enzyme activity alone was not associated with natriuresis, suggesting that medullary enzyme activity must be depressed for increased sodium excretion to occur during digoxin infusion. In high-dose experiments, significant inhibition of cortical and medullary enzyme in the contralateral control kidney was also observed, but natriuresis did not occur. In these experiments the rate at which digoxin reached the control kidney rose progressively but never equaled the rates in the directly infused kidney with either dose. Nevertheless, it is clear that under certain circumstances enzyme inhibition of either cortex or medulla need not be accompanied by natriuresis. We conclude that the major role of renal Na(+),K(+)-ATPase is in sodium reabsorption in the medulla (ascending limb of Henle's loop) and that it has a relatively small role in proximal sodium reabsorption. The kidney can rely on other sodium reabsorptive mechanisms depending on the rate of enzyme inhibition, so that natriuresis may not occur at all if depression in activity occurs "slowly." The nature of these mechanisms is not clear.
通过向犬的一侧肾动脉输注地高辛(该酶系统的特异性抑制剂),以0.4至0.9微克/千克/分钟(低剂量)和1.0至4.0微克/千克/分钟(高剂量)的剂量范围,进一步研究了肾钠钾ATP酶在钠重吸收中的作用。两个剂量范围均出现显著的利钠作用,同时伴有输注肾皮质和髓质钠钾ATP酶的抑制。尽管在许多实验中酶抑制率超过90%,但至少80%的滤过钠仍继续被重吸收。酶活性的百分比变化与地高辛给药速率和给药总量相关,但与钠排泄的变化无关。然而,髓质钠钾ATP酶活性的变化与游离溶质水重吸收分数(T(c)(H2O))的改变直接相关。单独抑制皮质酶活性与利钠作用无关,这表明在输注地高辛期间,为了增加钠排泄,髓质酶活性必须降低。在高剂量实验中,对侧对照肾的皮质和髓质酶也出现了显著抑制,但未发生利钠作用。在这些实验中,地高辛到达对照肾的速率逐渐升高,但在任何一个剂量下都从未达到直接输注肾的速率。然而,很明显,在某些情况下,皮质或髓质的酶抑制不一定伴有利钠作用。我们得出结论,肾钠钾ATP酶的主要作用是在髓质(亨氏袢升支)中进行钠重吸收,而在近端钠重吸收中作用相对较小。肾脏可以根据酶抑制的速率依赖其他钠重吸收机制,因此,如果活性降低“缓慢”,可能根本不会发生利钠作用。这些机制的性质尚不清楚。